Regenerex Pharma Enters Material Definitive Agreement

TL;DR

Regenerex Pharma just signed a big deal, could be a game-changer.

AI Summary

Regenerex Pharma, Inc. announced on September 3, 2025, that it has entered into a material definitive agreement. The company, formerly known as Peptide Technologies, Inc. and Eternelle Skincare Products Inc., is incorporated in Nevada and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing indicates a significant new contract or partnership for Regenerex Pharma, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement is a significant event, but the lack of specific details about the agreement's nature and terms introduces uncertainty.

Key Players & Entities

• REGENEREX PHARMA, INC (company) — Registrant
• Peptide Technologies, Inc. (company) — Former company name
• Eternelle Skincare Products Inc. (company) — Former company name
• September 3, 2025 (date) — Date of earliest event reported

FAQ

Filing Documents

• ixform8k.htm (8-K) — 24KB
• 0001472375-25-000103.txt ( ) — 180KB
• rgpx-20250903.xsd (EX-101.SCH) — 3KB
• rgpx-20250903_lab.xml (EX-101.LAB) — 33KB
• rgpx-20250903_pre.xml (EX-101.PRE) — 22KB
• ixform8k_htm.xml (XML) — 3KB

01 - Entry into a Material Definitive Agreement

Item 1.01 - Entry into a Material Definitive Agreement New Contract with Holista Colltech Ltd. As part of the Company's strategic advancement, Regenerex has entered into a licensing agreement with Holista Colltech Ltd . ("Holista"), a globally recognized producer of high-purity ovine collagen. This includes exclusive rights to use in wound care and distribution rights in the USA. Regenerex Pharma, Inc. Enters Into Binding Supply and Development Agreement with Holista Colltech Ltd. Sept 03, 2025- Las Vegas, NV- Regenerex Pharma, Inc (OTC: RGPX), a leading innovator in advanced wound closure systems for chronic wounds, today announced that it has entered into a binding supply and development agreement with Holista Colltech Ltd. of Perth, Australia. Under terms of the agreement, Holista will exclusively manufacture and supply its proprietary ovine collagen, including its patented 300 kDa intact collagen and nano-collagen technologies, for Regenerex's use in the development, clinical testing, and global distribution of advanced wound care products. The initial commercial focus will be the United States, with expansion into other global markets to follow. Key Terms of the Agreement - Exclusivity: Regenerex has exclusive worldwide rights to market Holista's collagen products for wound care applications. - Minimum Purchase Commitments: Regenerex is required to purchase a minimum of USD50,000 in 2025, scaling to USD3 million in 2026, USD6 million in 2027, and USD9 million annually from 2028 onwards. - Clinical Development: Regenerex will conduct and fund clinical studies and regulatory approvals with the U.S. FDA and other relevant authorities. - Joint Innovation: Both companies will collaborate on new applications of nano-collagen in advanced wound care, with joint ownership of any resulting intellectual property. - Manufacturing: Holista's ovine collagen will be drawn down from stocks from its manufacturing facility in Collie (WA) and nano

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized. REGENEREX PHARMA, INC. By: /s/ Greg Pilant Date: September 3, 2025 Name: Greg Pilant Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR